Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
Major reshuffle at drug controller's office - The Pharma Times | Pharma & Health Care News Portal
Categories: Regulatory Norms

Major reshuffle at drug controller’s office

Nine officials transferred recently; DCGI says move to bring transparency, accountability into the system

New Delhi February 1st, 2014: – At a time when the Indian drug regulator is under a spotlight following international scrutiny of domestic pharmaceutical companies, the government has ordered 
 in the Central Drug Standard Control Organisation (CDSCO), the office of the drugs controller general of India ().

As many as nine transfer orders were issued earlier this week, of which five are related to top officials in the CDSCO. While four deputy drug controllers (DDC) are transferred from this headquarter to different zonal offices, one DDC with additional charge of west zone is being brought back to the New Delhi headquarters. The transfer order, issued on January 27, has been reviewed by Business Standard.

Sources suggest the move comes in the wake of a recent corruption case in Hyderabad where a DDC was allegedly found accepting a bribe from a . However, DCGI G N Singh said the transfers are “isolated from any such case”. “We want to bring transparency and accountability into the system. We realised that the position of deputy is very sensitive and they need rotation, which will also give them more exposure,” Singh said.

The move assumes significance because of the events presently surrounding the drug manufacturing industry. As CDSCO has been in the spotlight for its lack of resources, inadequate monitoring of clinical trials and approval of new drugs, of late it has also been criticised for its failure to monitor drug manufacturing practices effectively.

The latest to come under the scanner is Ranbaxy Laboratories, whose India manufactured drugs are barred from the US. While DCGI has ordered inspection of the company’s Toansa facility, files related to various show-cause notices served to Ranbaxy and others were being handled by DDCs so far.

The four DDCs to be moved from the CDSCO headquarter are K Bangarurajan, A K Pradhan, S P Shani and S E Reddy.

Singh said such rotations would now be conducted every three years on an average.Business Line 

The Pharma Times News Bureau

Recent Posts

Fortis Hospital, Bannerghatta Road Launches dedicated Parkinson’s Disease and Deep Brain Stimulation Clinic

-  This specialized division empowers patients with neurological disorders to reclaim their mobility through a…

1 day ago

Milestone set in Indian Medical History – SSI Mantra Surgical Robotic System Performs the First-Ever Successful Surgery on One-Year-Old Infant

SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…

4 days ago

Manipal Hospital Ghaziabad organises Fire Safety Training to Enhance Emergency Response

Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…

2 weeks ago

Professor Dr Robert Zeiser receives DKMS Mechtild Harf Science Award 2024

DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…

2 weeks ago

Dr. Reddy’s launches drug-free migraine management device Nerivio® in Europe following successful launch in India

Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…

3 weeks ago

Ankura Hospital Doctors perform a successful Complex Lung Surgery on a 4-month-old Infant

 Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…

3 weeks ago